

Haematologica
HAEMATOL/2018/188193
Version 4

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34⁺CD123⁺ cells from acute myeloid leukemia / myelodysplastic syndrome patients and healthy donors

Rajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Trinh, Xiaokui Mo, Amber Gordon, Donna Bucci, David M. Lucas, Alice Mims, Christopher Brooks, Adrienne Dorrance, Alison Walker, William Blum, John C. Byrd, Gerard Lozanski, Sumithira Vasu, and Natarajan Muthusamy

Disclosures: C.B. is an employee of Stemline Therapeutics Inc. Funding source: OSU Comprehensive Cancer Center Leukemia Tissue Bank Shared Resource (P30 CA016058) JCB: R01 CA197844, R35 CA197734-01, D Warren Brown Foundation and the Lauber AML fund.

Contributions: R.M. planned, designed and performed experiments, analyzed data, wrote the drafts of the paper. S.G., B.G., R.R., R.W. and M.T. assisted with the experiments. X.M. performed the statistical analysis. A.G., D.B., D.M.L., C.B., A.D., A.W., W.B., J.C.B., and G.L. provided necessary reagents, supported components of the research. A. M, A.W., W.B. and S.V. contributed to the AML/MDS patient care, translation insight to the study. S.V. and N.M. conceived the idea, designed experiments, supervised the study, sought funding and reviewed drafts. All authors helped with revision of the draft and approved the final version for submission.